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Abstract
Background: Hepatocellular carcinoma (HCC) is one of the most popular cancers in the world with poor prognosis, which
often develops from chronic liver inflammatory diseases. Interleukin 23 (IL-23) is an inflammatory cytokine which is reported
to play an important role in tumor development in animal model. While the function of IL-23 in HCC development remains
unknown, so we investigate the role of IL-23 in HCC progression in this study.
Methodology and Principal Finding: Transcript level of IL-23, interleukin17A (IL-17A) and matrix metalloproteinases 9
(MMP9) in clinical HCC samples (n = 81) was determined by qPCR. Protein expression pattern of IL-23 in primary and
metastatic HCC tissues pairs (n = 49 pairs) was determined by immunohistochemistry staining. Cell migration, invasion, RNA
interfering and immune blotting were used to characterize the functional and signaling mechanisms in IL-23-treated HCC.
Compared with paired non-tumor tissue, higher IL-23 expression was detected in HCC tumor tissues with metastasis.
Immunohistochemistry staining confirmed the high expression of IL-23 in metastasis HCC. Immune blotting demonstrated
that IL-23 was highly expressed in HCC cell lines with metastasis. Functional study found that IL-23 could promote HCC cell
migration and invasion. Molecular analysis revealed that IL-23 could upregulate MMP9 expression via NF-kB/p65 signaling
activation and IL-17A could improve IL-23 expression in tumor cells directly via activating NF-kB/p65 signaling pathway.
Conclusions: IL-23 could promote HCC metastasis by the upregulation of MMP9 expression via activating NF-kB/p65
signaling pathway. At the same time, IL-17A could further promote IL-23 expression in HCC tumor cells.
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Introduction
Interleukin 23 (IL-23) and interleukin 12 (IL-12) belong to
interleukin 6 super-family [1]. IL-12/23 p40 is the common
subunit for them, which is covalently linked to either a p19 subunit
to form IL-23 or a p35 subunit to form IL-12 [1]. Both cytokines
are mainly expressed by activated dendrite cells or macrophages
under the stimulation of pathogens. IL-23 was also reported to be
secreted by tumor associated macrophages in tumor microenvi-
ronment [2].
Interestingly, IL-23 and IL-12 spur different immune pathways
[3]. IL-12 induces IFN-c-producing Th1 cells development and
enhances cytotoxic, anti-microbial and anti-tumor responses;
whereas IL-23 expands Th17 cells, which is mainly involved in
the pathology of autoimmunity and chronic inflammatory disease
[4]. Although the role of Th17 in tumor progression remains
controversial, the role of IL-23 in tumor incidence and metastasis
was established in mouse model. For example, mice lacking IL-
23p19 were resistant to DMBA/TPA-induced skin papilloma [5].
In another study, Stat3 signaling was shown to induce IL-23 as
well as inhibit IL-12 expression, thereby shifting the balance of
tumor immunity toward carcinogenesis [2]. Recently, IL-23 was
also reported to promote carcinogenesis and metastasis in the 39-
methylcholanthrene induced fibrosarcoma through suppressing
innate immune response [6].
However, the role of IL-23 in HCC progression is poorly
explored. In this study, we found that IL-23 was high expressed in
HCC tumor cells, especially in those with metastasis. We further
proved that IL-23 could directly promote HCC metastasis via NF-
kB/relA mediated MMP9 expression. We reported IL-17A was
high expressed in HCC with metastasis in another investigation
[7], so we further explored the relationship between IL-23 and IL-
17A in HCC progression. We found that IL-23 and IL-17A were
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highly correlated in HCC sample and IL-17A could promote IL-
23 expression in HCC cell lines directly.
Results
Expression of IL-23 is higher in HCC with metastasis
IL-23 mRNA expression in 81 paired HCC tissue demonstrated
that no significant difference of IL-23p19 expression was detected
between tumors and their non-tumor counterparts. However,
expression of IL-23p40 in tumors was significantly higher than
that in their non-tumor counterparts (P=0.003, paired-samples T
test). As IL-23 has been reported to be associated with tumor
metastasis in animal model, the expression of IL-23 was further
characterized in HCC with or without metastasis. The results
showed that both subunits of IL-23 were significantly higher
expressed in tumor area than that in non-tumor counterparts (for
p19, P=0.035; for p40, P=0.027, paired-samples T test) (Fig. 1A)
in 28 HCC with metastasis. While no significant different
expression was observed between tumors and their non tumor
counterparts (P=0.265 for p19 and P=0.754 for p40, paired-
samples T test) (Fig. 1A) in 53 HCC without metastasis.
Association study was further applied to investigate the clinical
significance of IL-23 expression in 81 HCC cases. The results
showed that tumor area IL-23 expression did not correlate to
patients’ age, gender, cirrhosis status, TNM stage and tumor size,
while tumor area IL-23 (p19 and p40) expression was significantly
correlated to patients’ metastasis status (Table 1). The result
suggested that IL-23 might play an important role in HCC
metastasis.
IL-23 is predominantly expressed in tumor cells
Protein expression of IL-23 was further detected by IHC
staining in 49 paired primary and metastatic HCC specimens. IL-
23 was predominantly detected in tumor cells with metastasis
(Fig. 1B). Interestingly, increasing IL-23 expression was often
observed in edge area, invading area, or blood vessel invading area
tumor cells (Fig. 1C). Among them, 28 pairs (57.1%) showed
higher, 2 pair (4.08%) showed weaker expression of IL-23 in
metastatic HCC than their respectively matched primary tumor
samples. 17 pairs (27.27%) showed the same expression in primary
and metastasis samples. And 2 pairs (4.08%) of them showed
negative expression.
Immune blotting was applied to determine protein expression
level of IL-23 in one immortalized liver cell lines (MiHA) and
seven HCC cell lines (HepG2, PLC8024, QGY7703, H2P, H2M,
Huh7 and MHCC-97L). The result demonstrated that both
subunits of IL-23 could be detected in all HCC cell lines (Fig. 1D).
RhIL-23 increases HCC cells motility
Wound healing and matrigel invasion assays were performed to
detect the effect of IL-23 on tumor cells motility as IL-23
expression level was proved to be associated with tumor metastasis.
The results demonstrated that rhIL-23 could remarkably promote
cell migration and invasion comparing to control parental cells
(Fig. 2A and 2B).
Knocking down IL-23 expression by RNAi inhibits cells
motility
To test whether the endogenous IL-23 is important for cancer
cell motility or not, we knocked down IL-23 expression in HCC
cells. As p40 expression is the restriction step for IL-23 expression
[1], Short hairpin RNA (shRNA) against IL-23p40 gene was used
to silence IL-23 expression in MHCC-97L cells. The result showed
that the endogenous expression of IL-23p40 could be efficiently
silenced in MHCC-97L cells at both mRNA (Fig. 3A) and protein
levels (Fig. 3B). Silencing IL-23p40 could effectively knock down
the endogenous expression of IL-23 in MHCC-97L, but had little
effect on the expression of IL-12 (data were not shown). Functional
study demonstrated that knocking down IL-23 expression could
significantly inhibit the wound healing (Fig. 3C) and invasive
abilities of MHCC-97L cells (Fig. 3D).
RhIL-23 up regulates MMP9 expression in HCC cells
As IL-23p19 knockout mice were reported to have decreased
MMP9 expression [5], which played an important role in tumor
metastasis [8], we studied whether IL-23 influenced HCC MMP9
expression or not. The result demonstrated that IL-23 increased
MMP9 mRNA expression in a dose dependent manner and
reached the peak after treatment for 12 hr (Fig. 4A). Immune
blotting assay also confirmed that rhIL-23 could increase MMP9
expression at protein level (Fig. 4B). IL-23 had no effect on the
expression of other MMPs including MMP1, MMP2, MMP3, and
MMP10 (data were not shown).
RhIL-23 up regulates MMP9 expression via activating NF-
kB/P65
As NF-kB is the key transcript factor for MMP9 expression [9],
we next investigated whether NF-kB also involved in IL-23
induced MMP9 expression or not. The result demonstrated that
the active form of NF-kB (P-P65) in cytoplasm was significantly
decreased while the level of which in nucleus was dramatically
elevated in PLC8024 and QGY-7703 cells after rhIL-23 treatment
for 6 hr (Fig. 4C). When helenalin, a NF-kB inhibitor, was added
to PLC8024 and QYG-7703 medium1 hr before rhIL-23
treatment, MMP9 mRNA expression was significantly decreased
(P,0.05, Independent Student’s t-test) (Fig. 4D). The result proved
that IL-23 increased MMP9 expression in HCC cells was
dependent on NF-kB/P65 activation.
RhIL-17A can promote IL-23 expression in HCC cell lines
via activating NF-kB/P65
As IL-17A and IL-23 are frequently reported to coexist in many
diseases [10], and IL-17A is also reported to promote HCC
metastasis [7], we further investigate the relationship between IL-
23 and IL-17A in HCC. We found that rhIL-17A (50 ng/mL)
could significantly increase the expression of IL-23 in PLC8024
and MHCC-97L cell lines at protein level (Fig. 5A). Further
investigation showed that rhIL-17A could significantly increase the
transcription level of IL-23p40 in HCC cell lines (PLC8024 and
MHCC-97L) (P,0.05), but had little influence on the transcrip-
tion expression of IL-23p19 (Fig. 5B). IL-17A was reported to
promote the NF-kB activation in HCC cell lines [7]. We next
verified whether the up-regulating effect of IL-17A on IL-23
expressions was also via the activation of NF-kB or not. When
helenalin, a NF-kB inhibitor, was added to PLC8024 and MHCC-
97L medium before rhIL-17A treatment, IL-23p40 mRNA
expression was significantly decreased (P,0.05, Independent
Student’s t-test) (Fig. 5C), which demonstrated that IL-17A
induced IL-23 expression in HCC cells was via NF-kB/P65
activation.
IL-23 is positively correlated with expression of MMP9
and IL-17A in clinical samples
qPCR result of MMP9, IL-17A and IL-23 mRNA expression in
81 clinical HCC specimens were further analyzed with SPSS16.0
software to confirm the correlation of MMP9, IL-17A and IL-23.
The results demonstrated that the mRNA expression of IL-23p19
IL-23 Promotes HCC Metastasis
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was significantly correlated with expressions of IL-17A (R= 0.36,
P,0.001) and MMP9 (R= 0.411, P,0.001) (Fig. 6) the expression
of IL-23p40 also significantly correlated with expression of IL-17A
(R= 0.337, P,0.001) and MMP9 (R= 0.349, P,0.001) (Fig. 6) in
clinical HCC samples.
Discussion
Recent investigations proved that IL-23 played an important
role in tumorigenesis through its immune suppression function
[2,5]. Here we found for the first time that IL-23 was high
expressed in HCC with metastasis. Invasion of the extracellular
matrix is the first step for tumor metastasis. To verify whether the
high expression of IL-23 in metastasis tumor cells was only the
marker for them or it could also promote tumor invasion and
migration, we treated HCC cell lines with rhIL-23 as well as
knocked down the endogenous IL-23 expression by RNAi. Results
demonstrated that IL-23 was not only the marker for metastatic
tumor cells, it could also promote tumor cells invasion and
migration directly, which implied that IL-23 was a potential
biomarker as well as a functional marker for metastasis HCC.
Twist mediated morphology change [11] and snail induced
EMT [12] are important events in tumor invasion and metastasis,
we did not observe significantly EMT change after rhIL-23
treatment (data were not shown). As increased MMPs expressions
are also reported to advance tumor metastasis [8,13], we followed
up to study whether IL-23 could influence MMPs expression or
not. The result verified that IL-23 could up regulate MMP9
expression in HCC cell lines. Data from clinical samples also
proved that MMP9 expression was highly (P,0.001) correlated
with IL-23 expression. As NF-kB is the key transcript factor for
MMP9 expression [9], we further investigated whether IL-23
could activate NF-kB signaling pathway or not. The result proved
that rhIL-23 could activate NF-kB through promoting the nucleus
translocation of P-P65. Further study proved that IL-23 increased
MMP9 expression could be efficiently inhibited by NF-kB
Figure 1. Expression of IL-23 in HCC and HCC cell lines. (A) Compare of IL-23 mRNA expression in 28 primary HCC with metastasis (M+) and 53
primary HCC without metastasis (M2) as well as their expression in tumor (T) and non-tumor (N) area. *, P,0.05; **, P,0.01. (B) Representative of IL-
23 expression in non-tumor, primary HCC and metastasis HCC by IHC staining (magnification 2006). (C) Representative of IL-23 expression in HCC by
IHC staining (magnification 2006). (D) Protein expression of IL-23 in HCC cell lines detected by western blot. b–actin was used as loading control.
doi:10.1371/journal.pone.0046264.g001
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inhibitor, which suggested that IL-23 increased MMP9 expression
was via the activation of NF-kB/p-p65 transcription factor.
In our recent study, IL-17A was found to high expressed in
HCC and can promote the metastasis of HCC [7]. As Il-23 and
IL-17A are frequently correlated in many diseases [10], we further
studied the correlation of IL-17A and IL-23 in HCC. It was
demonstrated that IL-17A could increase the expression of IL-23
in HCC tumor cells through promoting the transcriptional
expression of IL-23p40, which is the restriction expression subunit
for IL-23 expression. Clinical results from HCC samples further
confirmed the positive correlation of IL-23 and IL-17A.
Tumor metastasis is a multistage event, in which multiple
factors are involved. It requires the cancer cells to escape from the
primary tumor, survive in the circulation, seed at distant site and
grow. Each process is determined by the tumor cells as well as the
local tumor microenvironment. Tumor cells preserve the invasion
and migration ability is the admission for it. Then it may also need
the local tumor microenvironment to provide a permission status
for tumor cells to survive and even a status that could promote the
metastasis of malignant cells. High expression of IL-23 could help
to facilitate tumor metastasis in many aspects. Tumor cells with
high expression of IL-23 have higher invasion and migration
ability than their peers that have lower expression, which was
verified in the current study. The expression of IL-23 in tumor
microenvironment was reported to can attract macrophages [5],
which were reported to be obligated partners for tumor metastasis
[14]. In our study, the number of macrophages was significantly
increased around the high IL-23 expressed area (data were not
shown). IL-23 was also reported to act on Treg cells to suppress the
function of CD8 T cells in local tumor microenvironment [2].
Treg cells had been reported to locate in HCC local microenvi-
ronment and the increased frequency of which was correlated with
CD8 T-cell impairment and poor survival of HCC patients [15].
Materials and Methods
HCC samples and cell lines
HCC specimens for mRNA were obtained from 81 patients
underwent hepatectomy in the Sun Yat-Sen University Cancer
Center (Guangzhou, China). Among them, 28 with metastasis
including 8 intra-hepatic, 11 portal vein, and 9 extra-hepatic
metastasis (2 in gall bladder, 2 in greater omentum, 1 in lymph
node, 2 in colon and 2 in diaphragma). 49 pairs of primary and
matched metastatic HCC specimens were collected from archives
of paraffin embedded tissues in the Sun Yat-Sen University
Cancer Center, which included 32 intrahepatic (29 in portal vein
Table 1. Correlation of IL-23 expression1 with clinicopathological features in 81 HCC patients.
Clinicopathological Features Number (n =81) p19 (Mean ±SD)1 P value p40 (Mean ±SD)1 P value
Gender 0.384 0.229
Female 17 6.5264.67 5.5463.98
Male 64 4.1962.37 2.9861.07
Age 0.801 0.066
#50 46 4.4462.69 4.3961.94
.50 35 4.9963.43 2.3760.97
HBsAg2 0.046 0.085
Negative 19 10.2866.55 6.1863.65
Positive 59 3.0561.8 2.7361.07
Cirrhosis2 0.297 0.392
Absent 25 6.6464.62 4.4262.68
Present 54 3.9162.33 3.1361.29
Serum AFP (ng/ml)2 0.667 0.742
#25 22 4.2162.22 3.1962.97
.25 55 5.0162.99 3.7361.31
Tumor size (cm)2 0.603 0.071
#5 34 4.0663.39 2.3461.1
.5 46 5.262.77 4.3561.94
Tumor multiplicity2 0.701 0.577
Solitary 56 4.4662.5 2.9161
Multiple 22 5.4664.54 3.8763.24
TNM stage2 0.050 0.141
I–II 55 2.6360.97 2.7361.02
III–IV 24 9.3766.48 5.2863.21
Metastasis 0.014 0.003
No 53 2.1460.85 1.8260.48
Yes 28 9.4965.52 6.7263.01
1Expressions of p19 and p40 were detected by qPCR. Values are expressed as mean6SD.
2Partial data unavailable, statistics was done on the available data. Difference is considered significant when P,0.05 (shown in bold).
doi:10.1371/journal.pone.0046264.t001
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Figure 2. IL-23 promotes HCC cell migration and invasion. (A) RhIL-23 treated HCC cells (PLC8024 and QGY-7703) showed higher motility in
wound-healing assay, compared with BSA buffer control treated cells. (B) RhIL-23 increased cell invasion as detected by cell invasive assay.
Representatives of cells migrated through Matrigel-coated transwell were shown in the left panel (magnification 100). Total invasive cell number in
each chamber was summarized in the right panel. *, P,0.05.
doi:10.1371/journal.pone.0046264.g002
Figure 3. Knocking down IL-23 expression inhibits cell motility. (A), (B) IL-23 p40 expression was efficiently silenced by IL-23p40 shRNA as
determined by RT-PCR, qPCR (A) and western blot (B) in MHCC-97L cell. 18S and b-actin were used as loading control respectively. (C) and (D)
Compared to vector control the migration (C) and invasion (D) ability of IL-23 silenced cells were greatly decreased in MHCC-97L cell. *, P,0.05.
doi:10.1371/journal.pone.0046264.g003
IL-23 Promotes HCC Metastasis
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and 3 in intercostal vein) and 17 extrahepatic metastasis (2 in
greater omentum, 6 in lymph nodes, 3 in abdominal cavity, 1 in
inferior vena cava, 1 in adrenal cortex, 2 in peritoneum, 1 in
kidney and 1 in bone). Informed written consent was obtained
from each patient included in the study and the study protocol
conforms to the ethical guidelines of the 1975 Declaration of
Helsinki as reflected in a priori approval by the Committees for
Ethical Review of Research involving Human Subjects at Sun Yat-
Sen University Cancer Center. All used human HCC cell lines was
acquired and maintained as previously described [7,16].
Immunohistochemistry (IHC) staining
IHC staining was performed as previously described [7]. Briefly,
after blocking with normal goat serum or 5% BSA in PBS, The
slides were incubated with primary antibody against IL-23 P19
(mouse anti-IL-23 p19 diluted with 1:100, Biolegend, Minneapolis,
MN or rabbit anti-IL-23 P19 diluted with 1:500, Abcam, UK) at
4uC overnight in a moist chamber. Then followed up with second
antibody binding and detected with Diaminobenzidine tetrahy-
drochloride. To evaluate the IHC staining of IL-23p19, expression
of IL-23p19 was scored as negative, weak, moderate, and strong as
previously described [16]. Positively stained cells were scored by
two independently investigators under microscope.
Cell migration and invasion assay
Cell migration and invasion assay were performed as described
previously [7]. Briefly, cells were treated either with 50 ng/mL
recombinant human IL-23 (rhIL-23) (R&D System Minneapolis,
Figure 4. IL-23 upregulates MMP9 expression via activating NF-kB. (A) IL-23 promoted MMP9 mRNA expression at a dose and time
dependent manner shown by qPCR. (B) Expression of MMP9 was detected by western blot analysis in HCC cells treated with rhIL-23 (50 ng/mL) or
BSA buffer control for 24 hours. (C) Western blot analysis was used to detect whole cell, cytoplasm and nucleus level of P-P65 (active form of NF-kB)
expression in PLC8024 and QGY-7703 cells treated with rhIL-23 (50 ng/mL) at indicated time. (D) Expression of MMP9 detected by qPCR in PLC8024
and QGY-7703 cells with different treatment. BSA: treated with BSA buffer control; rhIL-23: treated with rhIL-23 (50 ng/mL); Helenalin+rhIL-23: treated
with helenalin (0.l mM) and rhIL-23 (50 ng/mL). *, P,0.05.
doi:10.1371/journal.pone.0046264.g004
Figure 5. IL-17A promots IL-23expression in HCC. (A) Expression of IL-23 was detected by western blot analysis in HCC cells treated with or
without rhIL-17A (50 ng/mL) for 24 hours. (B) Transcriptional expressions of both subunits of IL-23 were compared by qPCR between cells treated
with and without rhIL-17A (50 ng/mL) for 12 hours. *, P,0.05. (C) Transcriptional expression of IL-23p40 was detected by qPCR in PLC8024 and
MHCC-97L cells with different treatment. Control: without rhIL-17A treatment; rhIL-17A: treated with rhIL-17A (50 ng/mL); Helenalin+rhIL-17A: treated
with helenalin (0.l mM) and rhIL-17A (50 ng/mL). *, P,0.05.
doi:10.1371/journal.pone.0046264.g005
IL-23 Promotes HCC Metastasis
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MN) or BSA buffer control for described time and observed
accordingly.
RNA interference (RNAi) assay
MHCC-97L cells were transfected with a pGFP-RS plasmid
encoding IL-23p40 shRNA (Origene, Rockville MD) or a
scramble control pGFP-V-RS using Lipofectamine 2000 reagent
(Invitrogen, Carlsbad, CA) according to the manufacturer’s
instruction. Gene silencing efficiency was measured by real time
PCR, quantitative real-time PCR (qPCR) and western blotting
after stable pour selection with 1 ug/mL puromycin (Sigma-
Aldrich, St. Louis, MO).
Immune blotting
Whole cell lysates, Cytoplasm and Nuclear lysates were isolated
as described previously [7]and immune blotting were performed
with the standard protocol with antibodies against hIL-12P40
(abD Serotec, UK), b-actin, P-p65 (Santa Cruz Biotechnology,
Santa Cruz, CA), IL-17A (R&D Systems, Minneapolis, MN),
MMP9, histone H3 and hIL-23p19 (Abcam, UK).
qPCR
Total RNA extracting, cDNA amplifying and quantifying as
described previously [7]. The followings were primers used in this
investigation: IL-23P19 (Fw: 59-GGACAACAGTCAGTTCT-
GCTT-39; Rv: 59-CACAGGGCTATCAGGG AGC-39); IL-
23p40: (Fw: 59-ATGGTGAGCCGTGATTGTGC; Rv 59- AGG-
GAT TCCAGATTTTCTTTGC-39); 18 s: (59-CTCTTAGCT-
GAGTGTCCCGC-39, Rv: 59-CTGATCGTCTTCGAACCTC-
C-39; MMP9: (Fw: 59-GGGACGCAGACATCGT CATC-39; Rv:
59-TCGTCATCGTCGAAATGGGC-39); IL-17A: (Fw: 59-
CAATCCC ACGAAATCCAGGATG-39; Rv: 59- GTGGA-
GATTCCAAGGTGAGG -39).
Statistical analysis
All data were analyzed with SPSS software (version 16.0).
Comparisons between groups were analyzed by Student’s t-test.
The two-tailed chi-squared test was used to analyze the association
of IL-23 expression with HCC metastasis status. Correlation
between variables was determined by linear regression analysis.
Value of P,0.05 (two-tailed) was considered statistically signifi-
cant.
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